论文部分内容阅读
胃复安又名灭吐灵(Metaclopamioe),1984年由法国研制。它的药理作用主要表现在胃肠道和中枢神经系统,以胆硷样作用促进胃肠道运动和中枢化学催吐感受区(CTZ)起止吐作用等。目前巳广泛用于临床。 1.消化系统胃复安促进胃肠道运动在于:(1)增加胃和食管蠕动,从而促进胃排空;(2)增进十二指肠、小肠蠕动,加速食物通过十二指肠、空、回肠;(3)促进幽门活动和十二指肠球部扩张。因此可用于预防和治疗胀气性消化不良,胃滞留,糖尿病性胃轻瘫,慢性返流性食管炎,呃逆等。临床研究证明胃复安治疗返流性食管炎有效,推测可能为:(1)降低十二指肠和胃返流;(2)提高酸负荷的食道排空速度;(3)促进胃排空速度。Fink
Metoclopramide also known as Metoprolol (Metaclopamioe), developed in 1984 by France. Its pharmacological effects mainly in the gastrointestinal tract and the central nervous system, with choline-like role in promoting gastrointestinal motility and central chemical elicitor (CTZ) from antiemetic effect. Has been widely used in clinical. 1. Digestive system of metoclopramide to promote gastrointestinal motility is: (1) increased gastric and esophageal motility, thereby promoting gastric emptying; (2) to promote duodenal, intestinal peristalsis, accelerate the food through the duodenum, empty , Ileum; (3) to promote pyloric activity and duodenal bulb expansion. It can be used to prevent and treat flatulence indigestion, gastric retention, diabetic gastroparesis, chronic reflux esophagitis, hiccups and so on. Clinical studies have shown that metoclopramide is effective in treating reflux esophagitis, presumably as follows: (1) reduction of duodenum and gastric reflux; (2) increase of acid load esophageal emptying rate; (3) promotion of gastric emptying speed. Fink